2024 - Navigating the Investigational New Drug (IND) Application Process
Date2024-03-06
Deadline2024-03-06
VenueONLINE-VIRTUAL, USA - United States
KeywordsLife Sciences; Clinical Trials; Pharmaceutical Regulation
Topics/Call fo Papers
Discover an informative webinar delving into the investigational new drug (IND) application process, a pivotal milestone in drug development. The IND application is an important milestone in drug development. An IND aims to demonstrate every aspect of the drug is safe for human exposure. Sponsors need to evaluate IND readiness to ensure they have enough data to support the initiation of clinical trials. Submission of an incomplete IND lacking important studies or data can lead to a clinical hold, thus delaying clinical trials and increasing costs for the sponsor.
Join this webinar to explore the drug development process with specific insights into The Food and Drug Administration’s (FDA) regulations, including an overview of the required content for a successful IND application and recommended interactions with the agency to ensure success.
Keywords: Clinical Trials, FDA, Drug Approval, Clinical Research, Drug Safety, FDA Approval, Investigational New Drug, Regulatory, IND submission, CDMO/CMO, Toxicology/Safety
Join this webinar to explore the drug development process with specific insights into The Food and Drug Administration’s (FDA) regulations, including an overview of the required content for a successful IND application and recommended interactions with the agency to ensure success.
Keywords: Clinical Trials, FDA, Drug Approval, Clinical Research, Drug Safety, FDA Approval, Investigational New Drug, Regulatory, IND submission, CDMO/CMO, Toxicology/Safety
Other CFPs
- Development of CAR-T Cells for T-ALL Targeting CCR9
- AI-Powered Revolution in Life Sciences Translation
- Infectious Disease Diagnostics for Influenza, RSV and SARS-CoV-2
- Navigating the complexity of real-world healthcare data: choosing the right tools at the right time
- A Collaborative Approach to Advancing Access and Equity in Rare Disease Clinical Trials
Last modified: 2024-01-30 07:37:34